Company: DERM
Filing Date: 2025-08-28
Form Type: 8-K
Source: 0001104659-25-084879
Chunk: 0

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01.

Entry into a Material Definitive Agreement.

On August 28, 2025, Journey Medical Corporation
(the “ Company”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement”) with B. Riley Securities,
Inc. (“ B. Riley”) and Lake Street Capital Markets, LLC (“ Lake Street”), as sales agents or principals (each of
B. Riley and Lake Street, an “ Agent,” and together, the “ Agents”), under which the Company may offer and sell,
from time to time at its sole discretion, 3,750,000 shares of its common stock, par value $0.0001 per share (the “ Shares”),
through or to the Agents. The issuance and sale, if any, of Shares by the Company under the Sales Agreement will be made pursuant to the
Company’s registration statement on Form S-3 (File No. 333-269079), which was originally filed with the Securities and Exchange
Commission (the “ SEC”) on December 30, 2022 and declared effective on January 26, 2023, and the prospectus supplement, dated
and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “ Securities Act”)
on August 28, 2025.

Under the Sales Agreement, the Agents may sell
Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities
Act. The Agents will use commercially reasonable efforts to sell the Shares from time to time, based upon instructions from the Company
(including any price, time or size limits or other customary parameters or conditions the Company may impose). The Sales Agreement contains
customary representations, warranties, and agreements of the Company and the Agents. The Company will pay each Agent a commission
of 3.0% of the gross proceeds from the sales of Shares sold through such Agent under the Sales Agreement and has provided the Agents with
customary indemnification and contribution rights. The Company will also reimburse the Agents for certain expenses incurred in connection
with the Sales Agreement.

The Company is not obligated to make any sales
of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the
sale of all Shares subject to the Sales Agreement or (ii) the termination of the Sales Agreement in accordance with its terms.

The foregoing